Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daito Pharmaceutical Co's Enterprise Value is 円46,012 Mil.
Daito Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 was 円0 Mil. Therefore, Daito Pharmaceutical Co's EV-to-FCF for today is .
The historical rank and industry rank for Daito Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4577'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 11.06
Current: 11.06
During the past 13 years, the highest EV-to-FCF of Daito Pharmaceutical Co was 11.06. The lowest was 0.00. And the median was 0.00.
TSE:4577's EV-to-FCF is ranked better than 75.44% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs TSE:4577: 11.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Daito Pharmaceutical Co (TSE:4577) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Daito Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Daito Pharmaceutical Co's share price for today is 円1309.00.
Daito Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円107.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's EV-to-FCF falls into.
Daito Pharmaceutical Co's current Enterprise Value is 円46,012 Mil.
Daito Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円1,309.00 is trading 2.4% above its estimated GF Value™ of 円1,278.76.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
EV-to-FCF:
GF Value™: 円1,278.76 vs. price of 円1,309.00 (2.4% above fair value)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
